Abstract
PLG potentiates the action of levodopa in 6-OH-DA-treated rats. PLG plus levodopa is more effective than levodopa alone. PLG-treated rats have a decreased concentration of Leu-enkephalin in the caudate nucleus as compared with the control. Preliminary results of using PLG (400 mg/day) for 10 days for treating PD are satisfactory. The mode of action of PLG with relation to dopamine-enkephalin interaction is discussed.
MeSH terms
-
Aged
-
Animals
-
Antiparkinson Agents / therapeutic use*
-
Brain / drug effects
-
Enkephalin, Leucine / metabolism
-
Female
-
Humans
-
Hydroxydopamines / toxicity
-
Levodopa / therapeutic use
-
MSH Release-Inhibiting Hormone / therapeutic use*
-
Male
-
Middle Aged
-
Oxidopamine
-
Parkinson Disease / drug therapy*
-
Parkinson Disease, Secondary / chemically induced
-
Parkinson Disease, Secondary / drug therapy
-
Rats
-
Stereotyped Behavior / drug effects
Substances
-
Antiparkinson Agents
-
Hydroxydopamines
-
Levodopa
-
Enkephalin, Leucine
-
Oxidopamine
-
MSH Release-Inhibiting Hormone